|
|
Article: Metabolex's Multi-Part Deal With Ortho: $548M Potential.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
West Coast Editor
Just after kicking off a Phase II/III trial with its lead insulin sensitizer, metaglidasen, in Type II diabetes, Metabolex Inc. entered a development and commercialization deal with Ortho-McNeil Inc. for that indication, as well as obesity and dyslipidemia, worth up to $548 million plus royalties.
The agreement includes metaglidasen and MBX-2044, as well as follow-on compounds for which Ortho, a subsidiary of Madison, N.J.-based Johnson & Johnson, gets an exclusive license.
"We have agreed upon plans, all the way to registration, for both of those compounds," said Harold Van Wart, president and CEO of Hayward, Calif.-based ...